 |
| |
04.26 |
Established by the current president Kim, Seung Ho
of Boryung Pharmaceutics |
|
 |
| |
04.30 |
Reconstruction of Jinchun factory and completion of the KGMP factory for the production of biological medicine |
| |
07.02
|
Recognized as an eligible KGMP Oral and Solid dosage form manufacturer
|
| |
08.06
|
Recognized as an eligible KGMP injectionmanufacturer
|
| |
09.07
|
The first production and marketing of influenza HA vaccine.
|
|
 |
| |
03.25 |
Passed the domestic test on Zerotyph Capsule (the second oral antityphoid vaccine in the world) for the first time and launched the sale
|
|
 |
| |
01.31 |
Switzerland (the initial developer of the oral vaccine) acknowledged the manufacturing technology of Zerotyph as superior
to that of its own and acquired patents (currently in 13 countries)
|
| |
07.21 |
Recognized as an eligible KGMP Oral Solution manufacturer
|
| |
09.06 |
Recognized as an eligible KGMP lyophilized medicine manufacturer Acquired recognition as an eligible KGMP manufacturer
of all forms of vaccine (Oral Solution, lyophilized vaccine, Oral and Solid form vaccine)
|
|
 |
| |
01.07 |
Obtained authorization from Korea Science Technology Association of the annex research center
|
| |
06.01 |
Merged with Boryung Chemistry to strengthen the management of Boryung Pharmaceutical
|
|
 |
| |
11.20 |
Boryung Pharmaceutical¡¯s revenue surpassed 10 billion KRW
|
|
 |
| |
06.26 |
Completed construction of office building (consisting of two floors above ground and one below ground) within the Jinchun factory site
|
|
 |
| |
02.02 |
Obtained the license to retail medical and pharmaceutical products
|
|
 |
| |
04.26 |
Changed company name from Boryung Pharmaceutics Inc. to Boryung Biopharma Co.
|
|
 |
| |
05.21 |
Began affiliation with Catholic Medical School for umbilical cord blood cell (UCB) program
|
| |
 |
Donation of 100 million KRW to the UCB Bank in Catholic University after the affiliation
|
| |
|
Donation for the operation of UCB Cell Bank (for 3 years from 2004 to 2006)
|
| |
|
Donation for the treatment of child leukemia patients in Catholic Hospital (for 3 years from 2004 to 2006)
|
| |
06.30 |
Began affiliation with Youngnam Medical University for UCB Cell program
|
| |
|
Donation of 100 million KRW for the establishment and the operation of UCB Cell Bank in Youngnam University
|
| |
07.01 |
Opening of Boryung i-Mom Cell (beginning of true commitment toward UCB Cell Program)
|
|
 |
| |
11.30 |
Boryung Pharmaceutical¡¯s revenue surpassed 20 billion KRW
|
|
 |
| |
05.25 |
Contracted vaccine incorporation deal with Indian corporation SIIL
|
| |
08.30 |
Exceeded 1,000 UCB membership contract per month (Number of new memberships in Aug. 2005: 1,085)
|
|
|
|
| |
09.09 |
Contracted Japanese UCB Cell storage affiliation with Japanese corporation CBT
|
|
 |
| |
01.13 |
Completed extension of GMP factory (for biological medicine) in Jinchun site
|
|
